Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ICOS costimulation in inflammatory bowel disease.

Takanori Kanai1, Teruji Totsuka, Katsunari Tezuka

  • 1Department of Gastroenterology and Hepatology, Graduate School, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.

Journal of Gastroenterology
|February 8, 2003
PubMed
Summary

Researchers are exploring inducible costimulator (ICOS) as a targeted therapy for inflammatory bowel disease (IBD). This approach aims to ameliorate harmful immune responses without causing general immunosuppression, offering a potential new treatment for IBD patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Better Peptides via Chemical Glycosylation: Somatostatin Analogues Having a Human Complex-Type N-Glycan with Improved Drug Properties.

Chemistry (Weinheim an der Bergstrasse, Germany)·2023
Same author

Smoking and drinking habits relating to development of ulcerative colitis in Japanese: A multicenter case-control study.

JGH open : an open access journal of gastroenterology and hepatology·2023
Same author

Fulminant Amebic Enteritis in the Perinatal Period.

Internal medicine (Tokyo, Japan)·2022
Same author

Serum Leucine-Rich α2 Glycoprotein: A Novel Biomarker for Transmural Inflammation in Crohn's Disease.

The American journal of gastroenterology·2022
Same author

Transmural Remission Characterized by High Biologic Concentrations Demonstrates Better Prognosis in Crohn's Disease.

Journal of Crohn's & colitis·2022
Same author

Suspension culture in a rotating bioreactor for efficient generation of human intestinal organoids.

Cell reports methods·2022

Area of Science:

  • Immunology
  • Gastroenterology
  • Pharmacology

Background:

  • Current immunotherapies for diseases like IBD are often unsatisfactory, requiring long-term or high-dose immunosuppressants.
  • Existing treatments struggle to predict disease onset and can lead to general immunocompromise.
  • There is a need for selective immunotherapies that target pathogenic responses without compromising the patient's overall immunity.

Purpose of the Study:

  • To investigate the potential of inducible costimulator (ICOS) as a targeted therapeutic molecule for inflammatory bowel disease (IBD).
  • To evaluate ICOS as a strategy for ameliorating pathogenic immune responses in IBD patients.
  • To explore a more selective immunotherapy approach for IBD treatment.

Main Methods:

  • The study focuses on the molecular characteristics of ICOS.

Related Experiment Videos

  • It analyzes the potential of targeting ICOS for therapeutic intervention in IBD.
  • The research discusses the implications of ICOS blockade or modulation in the context of immune responses.

    • Main Results:

    • Inducible costimulator (ICOS) is identified as an inducible and inflammatory site-specific molecule.
    • ICOS shows promise as an ideal targeting molecule for treating human IBD.
    • Targeting ICOS may offer a selective approach to ameliorate pathogenic immune responses.

    Conclusions:

    • Inducible costimulator (ICOS) represents a promising target for developing selective immunotherapies for IBD.
    • Targeting ICOS could provide a more effective and less immunosuppressive treatment strategy for IBD patients.
    • Further research into ICOS-based therapies is warranted for managing inflammatory bowel disease.